Finally, AVMs are a series of high-flow vascular disorders caused by predominantly somatic mutations, although some are germline, as in capillary malformation-arteriovenous malformation [33]., MEK/MAPKK (Mitogen-Activated Protein Kinase Kinase) inhibitors targeted against somatic MAP2K1 mutations are being developed to be used as primary or adjuvant therapy in managing peripheral AVMs [34]. This evidence concerns the gene MAP2K7 and arteriovenous hemangioma/malformation.